Company*
(Country; Symbol)

Company*
(Country; Symbol)

Type/Product Area

Terms/Details (Date)
November

Horizon Pharma Inc.*

Mundipharma International Corp. Ltd.* (UK)

Exclusive distribution and supply agreements for commercialization of Lodotra in Australia, China, Hong Kong, Indonesia, Korea, Malaysia, New Zealand, the Philip-pines, Singapore, South Africa, Taiwan, Thailand and Vietnam

Lodotra is a programmed-release formulation of low-dose prednisone; financial terms were not disclosed (11/8)

Nautilus Neurosciences Inc.*

Tribute Pharmaceuticals* (Canada)

Exclusive license agreement for the commercialization of Cambia in Canada

Cambia is approved in the U.S. for migraine (11/17)
December

ImVisioN Therapeutics AG* (Switzerland)

IDT Biologika* (Germany)

Partnership for manufacturing of ImVisioN's immunotherapy product candidates

Specific financial terms were not disclosed, though IDT plans to make an equity investment in ImVisioN (12/17)

Notes:

* Private companies are indicated with an asterisk.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.